Cancer Survivorship: Protecting the heart
Blocking a protein known as EPAC1 may prevent the development of heart-related side effects caused by a chemotherapy drug.
- Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Australia
- Adelaide Medical School, University of Adelaide, Australia
Advances in medical sciences mean that some cancers can now be cured or treated as chronic diseases which can be managed over long periods of time. This has led to the emerging field of cancer survivorship, which includes preventing and managing the side effects of cancer treatments (Emery et al., 2022).
For example, chemotherapy drugs called anthracyclines are used to treat haematologic cancers and cancers affecting solid organs in both adults and children. However, they can also lead to heart damage in around 20% of adults within two to three years of treatment, and in children up to 30 years after the initial exposure (Limat et al., 2003; Oeffinger et al., 2006; Romond et al., 2012).
Anthracyclines may cause DNA damage that leads to cell death, but it is unclear why the heart is affected over other organs (Tan et al., 2015). Clinicians sometimes use cardioprotective drugs, such as dexrazoxane, to prevent the toxic side effects of anthracyclines (US Food and Drug Administration, 2014). However, cardioprotective drugs are not always used due to concerns that they may reduce how the tumour responds to treatment, as well as causing side effects (Swain et al., 1997; Shaikh et al., 2016). A better understanding of the mechanisms underlying anthracycline-induced cardiotoxicity is therefore essential to develop more effective preventive strategies.
Now, in eLife, Eric Morel, Christophe Lemaire and colleagues – including Marianne Mazevet as first author – report on how blocking a specific protein appears to prevent anthracycline-induced heart damage (Mazevet et al., 2023). The researchers (who are based at various institutes in France, Switzerland and the United States) exposed rat cardiac cells and live mice to an anthracycline called doxorubicin; they then examined how the cardiotoxicity of this drug was affected by the protein EPAC1, which contributes to heart failure by modifying cardiac cells (Surinkaew et al., 2019).
First, Mazevet et al. showed that rat cardiac cells treated with doxorubicin displayed signs of DNA damage, and that signalling enzymes linked to apoptosis were being activated. The drug also increased the activity of EPAC1, as well as its expression. This latter effect was also observed in live mice treated with doxorubicin. However, EPAC2 – the isoform of EPAC1 – does not appear to be involved in the response.
Pharmacological inhibition of EPAC1 in rat cardiac cells reduced the activation of apoptotic pathways caused by doxorubicin; notably, the inhibitor also provided the same level of protection against cardiac toxicity as the cardioprotective drug dexrazoxane. Experiments on live mice provided further insights into the interactions between EPAC1 and doxorubicin. Knock-out animals lacking the EPAC1 gene showed no signs of cardiotoxicity when administered doxorubicin, while wild-type animals displayed increased EPAC1 expression and decreased cardiac contractility after 6 weeks of treatment (Figure 1). However, this knock-out study did not investigate other potential manifestations of cardiotoxicity such as irregular heartbeats or more subtle cardiac abnormalities.
Figure 1
Loss of EPAC1 reduces heart damage in mice receiving doxorubicin.
Table showing the prevention of doxorubicin-induced cardiomyopathy in wild-type and EPAC1 knockout mice (i.e., mice without the EPAC1 gene). Increased EPAC1 expression was seen in wild-type mice receiving doxorubicin who also developed cardiomyopathy.
Image credit: Illustrations adapted from SciDraw (CC BY 4.0): mouse by Ethan Tyler and Lex Kravitz, syringe by Hassan Ghayas, heart by John Chilton and DNA strands by Guilherme Bauer Negrini.
Finally, EPAC1 inhibition enhanced the cytotoxic effect doxorubicin had on breast and cervical human cancer cells grown in the laboratory. It will be necessary to confirm the anticancer effects of this drug in live animals, and in combination with the other available anthracyclines. If such combinations were confirmed to have an additive anticancer effect, a lower dose of anthracyclines may then be required, which would further reduce the risk of cardiotoxicity.
In conclusion, Mazevet et al. have demonstrated the critical role of EPAC1 in triggering the signalling pathways involved in anthracycline-induced cardiotoxicity. Both the pharmacologic inhibition of EPAC1 and knocking out the gene for this protein in mice prevented the cancer drug doxorubicin from causing heart damage, suggesting a promising avenue of research for preventing cardiotoxicity in patients treated with anthracyclines.
While pharmacologically inhibiting EPAC1 was shown to be effective in rat heart cells grown in the laboratory, Mazevet et al. did not test the compound in vivo. Also, as only a single concentration of the inhibitor was studied, the potential dose-response relationship remains unclear. Further studies are needed to assess the pharmacokinetics and tolerability of the inhibitor for EPAC1 in animal models, as well as any possible drug interactions. An examination of the molecular structure of the compound may reveal potentially reactive groups. Consideration will also need to be given to the route of administration in future preclinical and human studies.
References
-
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphomaAnnals of Oncology 14:277–281.https://doi.org/10.1093/annonc/mdg070
-
Chronic health conditions in adult survivors of childhood cancerThe New England Journal of Medicine 355:1572–1582.https://doi.org/10.1056/NEJMsa060185
-
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerJournal of Clinical Oncology 30:3792–3799.https://doi.org/10.1200/JCO.2011.40.0010
-
Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysisJournal of the National Cancer Institute 108:djv357.https://doi.org/10.1093/jnci/djv357
-
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancerJournal of Clinical Oncology 15:1318–1332.https://doi.org/10.1200/JCO.1997.15.4.1318
-
Anthracycline-induced cardiomyopathy in adultsComprehensive Physiology 5:1517–1540.https://doi.org/10.1002/cphy.c140059
Article and author information
Author details
Publication history
- Version of Record published: September 6, 2023 (version 1)
Copyright
© 2023, Inglis and Mangoni
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 162
- views
-
- 21
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cancer Survivorship: Protecting the heart
eLife 12:e91831.
https://doi.org/10.7554/eLife.91831
Further reading
-
- Cancer Biology
Certain bacteria demonstrate the ability to target and colonize the tumor microenvironment, a characteristic that positions them as innovative carriers for delivering various therapeutic agents in cancer therapy. Nevertheless, our understanding of how bacteria adapt their physiological condition to the tumor microenvironment remains elusive. In this work, we employed liquid chromatography-tandem mass spectrometry to examine the proteome of E. coli colonized in murine tumors. Compared to E. coli cultivated in the rich medium, we found that E. coli colonized in tumors notably upregulated the processes related to ferric ions, including the enterobactin biosynthesis and iron homeostasis. This finding indicated that the tumor is an iron-deficient environment to E. coli. We also found that the colonization of E. coli in the tumor led to an increased expression of lipocalin 2 (LCN2), a host protein that can sequester the enterobactin. We therefore engineered E. coli in order to evade the nutritional immunity provided by LCN2. By introducing the IroA cluster, the E. coli synthesizes the glycosylated enterobactin, which creates steric hindrance to avoid the LCN2 sequestration. The IroA-E. coli showed enhanced resistance to LCN2 and significantly improved the anti-tumor activity in mice. Moreover, the mice cured by the IroA-E. coli treatment became resistant to the tumor re-challenge, indicating the establishment of immunological memory. Overall, our study underscores the crucial role of bacteria’s ability to acquire ferric ions within the tumor microenvironment for effective cancer therapy.
-
- Cancer Biology
- Cell Biology
Mutations in the gene for β-catenin cause liver cancer cells to release fewer exosomes, which reduces the number of immune cells infiltrating the tumor.
